We report results of a pilot clinical study of a subcutaneous fluorescence affinity sensor (FAS) for continuous glucose monitoring conducted in people with type 1 and type 2 diabetes. The device was assessed based on performance, safety, and comfort level under acute conditions (4 h).
Research Design and Methods:
A second-generation FAS (BioTex Inc., Houston, TX) was subcutaneously implanted in the abdomens of 12 people with diabetes, and its acute performance to excursions in blood glucose was monitored over 4 h. After 30–60 min the subjects, who all had fasting blood glucose levels of less than 200 mg/dl, received a glucose bolus of 75 g/liter dextrose by oral administration. Capillary blood glucose samples were obtained from the finger tip. The FAS data were retrospectively evaluated by linear least squares regression analysis and by the Clarke error grid method. Comfort levels during insertion, operation, and sensor removal were scored by the subjects using an analog pain scale.
Results:
After retrospective calibration of 17 sensors implanted in 12 subjects, error grid analysis showed 97% of the paired values in zones A and B and 1.5% in zones C and D, respectively. The mean absolute relative error between sensor signal and capillary blood glucose was 13% [±15% standard deviation (SD), 100–350 mg/dl] with an average correlation coefficient of 0.84 (±0.24 SD). The actual average “warm-up” time for the FAS readings, at which highest correlation with glucose readings was determined, was 65 (±32 SD) min. Mean time lag was 4 (±5 SD) min during the initial operational hours. Pain levels during insertion and operation were modest.
Conclusions:
The in vivo performance of the FAS demonstrates feasibility of the fluorescence affinity technology to determine blood glucose excursions accurately and safely under acute dynamic conditions in humans with type 1 and type 2 diabetes. Specific engineering challenges to sensor and instrumentation robustness remain. Further studies will be required to validate its promising performance over longer implantation duration (5–7 days) in people with diabetes.
The Diabetes Control and Complication Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993; 329 (14): 977–86.
4.
HanssenKFDahl-JørgensenKLauritzenTFeldt-RasmussenBBrinchmann-HansenODeckertT. Diabetic control and microvascular complications: The near-normoglycaemic experience. Diabetologia.1986; 29 (10): 677–84.
5.
KlonoffDC. Continuous glucose monitoring: Roadmap for 21st century diabetes therapy. Diabetes Care.2005; 28 (5): 1231–9.
FeldmanBBrazgRSchwartzSWeinsteinR. A continuous glucose sensor based on wired enzyme technology—results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther.2003; 5 (5): 769–79.
8.
The Diabetes Research in Children Network (DirecNet) Study Group.The accuracy of the Freestyle NavigatorTM continuous glucose monitoring system in children with type 1 diabetesDiabetes Care.2007; 30 (1): 59–64.
9.
GargSKSchwartzSEdelmanSV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care.2004; 27 (3): 734–8.
10.
GargSZisserHSchwartzSBaileyTKaplanREllisSJovanovicL. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care29: 44–50, 2006.
11.
SteilGMRebrinKDarwinCHaririFSaadMF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes.2006; 55 (12): 3344–50.
12.
WeinzimerSASteilGMSwanKLDziuraJKurtzNTamborlaneWV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care.2008; 31 (5): 934–9.
13.
El-KhatibFHRussellSJNathanDMSutherlinRGDamianoER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med.2010; 2 (27): 27ra27.
14.
HovorkaRKumareswaranKHarrisJAllenJMElleriDXingDKollmanCNodaleMMurphyHRDungerDBAmielSAHellerSRWilinskaMEEvansML. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: Crossover randomised controlled studies. BMJ.2011; 342: d1855.
15.
MuscatelloMMStunjaLEAsherSA. Polymerized crystalline colloidal array sensing of high glucose concentrations. Anal Chem.2009; 81 (12): 4978–86.
TierneySFalchBMHjelmeDRStokkeBT. Determination of glucose levels using a functionalized hydrogel-optical fiber biosensor: Toward continuous monitoring of blood glucose in vivo. Anal Chem.2009; 81 (9): 3630–6.
18.
SchultzJSSimsG. Affinity sensors for individual metabolites. Biotechnol Bioeng Symp.1979;(9): 65–71.
19.
BallerstadtREvansCGowdaAMcNicholsR. In vivo performance evaluation of a transdermal near- infrared fluorescence resonance energy transfer affinity sensor for continuous glucose monitoring. Diabetes Technol Ther.2006; 8 (3): 296–311.
20.
BallerstadtREvansCGowdaAMcNicholsR. Fiber-coupled fluorescence affinity sensor for 3-day in vivo glucose sensing. J Diabetes Sci Technol.2007; 1 (3): 384–93.
21.
BallerstadtRGowdaAMcNicholsR. Fluorescence resonance energy transfer-based near-infrared fluorescence sensor for glucose monitoring. Diabetes Technol Ther.2004; 6 (2): 191–200.
DiemPKaltLHaueterUKrinelkeLFajfrRReihlBBeyerU: Clinical performance of a continuous viscometric affinity sensor for glucose. Diabetes Technol Ther.2004; 6 (6): 790–9.
24.
ChinnayelkaSZhuHMcShaneM. Near-infrared resonance energy transfer glucose biosensors in hybrid microcapsule carriers. J Sensors.2008; 346016.
25.
SchultzJSMansouriSGoldsteinIJ. Affinity sensor: A new technique for developing implantable sensors for glucose and other metabolites. Diabetes Care.1982; 5 (3): 245–53.
26.
MansouriSSchultzJS. A miniature optical glucose sensor based on affinity binding. Nature Biotechnol.1984; 2: 885–90.
27.
MeadowsDLSchultzJS. Design, manufacture and characterization of an optical fiber glucose affinity sensor based on a homogenous fluorescence energy transfer assay system. Anal Chim Acta.1993; 280: 21–30.
28.
BallerstadtRSchultzJS. Competitive-binding assay method based on fluorescence quenching of ligands held in close proximity by a multivalent receptor. Anal Chim Acta.1997; 345 (3–1): 203–12.
29.
RussellRJPishkoMVGefridesCCMcShaneMJCotéGL. A fluorescence-based glucose biosensor using concanavalin A and dextran encapsulated in a poly(ethylene glycol) hydrogel. Anal Chem.1999; 71 (15): 3126–32.
30.
TolosaLMalakHGaoRLakowiczJR. Optical assay for glucose based on luminescence decay time of the long wavelength dye Cy5™. Sensors Actuators B Chemicals.1997; 45: 93–99.
31.
BallerstadtREvansCMcNicholsRGowdaA. Concanavalin A for in vivo glucose sensing: A biotoxicity review. Biosens Biolectron.2006; 22 (2): 275–84.
32.
Dutt-BallerstadtREvansCGowdaAMcNicholsR. Preclinical in vivo study of a fluorescence affinity sensor for short-term continuous glucose monitoring in a small and large animal model. Diabetes Technol Ther.2008; 10 (6): 453–60.
33.
WongDLHockenberry-EatonMWilsonDWinkelsteinMLAhmannEDiVito-ThomasPA. Whaley and Wong's nursing care of infants and children. 6th ed.St. Louis: Mosby; 1999.
34.
DemingWE. Statistical adjustment of data. New York: Dover; 1964.
35.
ClarkeWLCoxDGonder-FrederickLACarterWPohlSL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care.1987; 10 (5): 622–8.
36.
WangJPiersonRNJr. Disparate hydration of adipose and lean tissue require a new model for body water distribution in man. J Nutr.1976; 106 (12): 1687–93.
37.
PunithaSHariBN VedhaKarthikeyanD. Enhancement of celecoxib solubility by solid dispersion using mannitol. Int J Pharm Pharm Sci.2010; 2 (4): 109–11.
38.
GuerciBFloriotMBöhmePDurainDBenichouMJellimannSDrouinP. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care.2003; 26 (3): 582–9.
39.
MetzgerMLeibowitzGWainsteinJGlaserBRazI. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care.2002; 25 (7): 1185–91.
40.
Food and Drug Administration.Summary of safety and effectiveness data for the MiniMed Continuous Glucose Monitoring System (CGMS). PMA P980022. Rockville: Food and Drug Administration; 1999.
41.
Food and Drug Administration.DexComTM STSTM Continuous Glucose Monitoring System. PMA P050012. Rockville: Food and Drug Administration; 2006.
42.
Food and Drug Administration.Summary of safety and effectiveness data for the FreeStyle Navigator continuous glucose monitoring system. PMA P050020. Rockville: Food and Drug Administration; 2008.
43.
MaranACrepaldiCTiengoAGrassiGVitaliEPaganoGBistoniSCalabreseGSanteusanioFLeonettiFRibaudoMDi MarioUAnnuzziGGenoveseSRiccardiGPrevitiMCucinottaDGiorginoFBellomoAGiorginoRPosciaAVaralliM. Continuous subcutaneous glucose monitoring in diabetic patients: A multicenter analysis. Diabetes Care.2002; 25 (2): 347–52.
44.
LinkeBKiwitMThomasKKrahwinkelMKernerW. Prevention of the decrease in sensitivity of an amperometric glucose sensor in undiluted human serum. Clin Chem.1999; 45 (2): 283–5.
45.
DesaiMAGhoshSCrumpPWBenmakrohaYVadgamaPM. Internal membranes and laminates for adaptation of amperometric enzyme electrodes to direct biofluid analysis. Scand J Clin Lab InvestSuppl.1993; 214: 53–60.
